(PRWEB) December 15, 2014
Cancer researchers have just published an important new report on the possible underlying genetic causes of deadly malignant pleural mesothelioma. Surviving Mesothelioma has just posted an article on the research on their website. Click here to read it now.
Doctors at Harvard, MIT, the University of Hawaii Cancer Center, and New York’s Langone Medical Center performed complete genetic analyses on 22 malignant pleural mesothelioma patients in an effort to pinpoint the genes that are most likely to be altered in the disease.
“Integrative analysis of mutations and somatic copy number alternations (SCNAs) revealed frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1,” reports author Dr. Guangwu Guo of the Broad Institute of Harvard and MIT.
Past studies have focused on only small groups of genes involved in mesothelioma development, but the new study is the first to analyze the entire exome.
“This study is important because it gives us, for the first time, a more complete picture of mechanism by which mesothelioma develops,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “This kind of understanding is a vital first step toward developing new kinds of treatments and saving more lives.”
To read the full story on genetic mutations in mesothelioma, see Multi-Center Study Reveals “Genomic Basis” of Mesothelioma, available now on the Surviving Mesothelioma website.
Guo, G, “Whole exome sequencing reveals frequent genetic alternations in BAP1, NF2, CDKN2A and CUL1 in malignant pleural mesothelioma”, December 8, 2014, Cancer Research, Epub ahead of print, http://www.ncbi.nlm.nih.gov/pubmed/25488749
For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.